First FDA Recognition for Tumor Marker Database

November 19, 2021

In the 20 years since the first targeted cancer therapy was approved, more than 100 such products are now on the market or in development. These targeted drugs offer a different approach to the carpet bombing of chemotherapy — they are precise missiles, homing in on specific targets in the tumor's genetics.

Last month, the US Food and Drug Administration (FDA) granted its first recognition of a precision-oncology knowledge base linking genetic biomarkers to specific cancer types —

the Memorial Sloan Kettering Cancer Center's Oncology Knowledge Base (OncoKB). In October, OncoKB became the first tumor-mutation database to be included in the FDA's database recognition program.

 The list includes MSKCC's own CBioPortal, as well as MyCancerGenome, the Precision Medicine Knowledge Base, Cancer Genome Interpreter, Cancer Driver Log, Tumor Portal, and others.

肿瘤标志物数据库首次获得 FDA 认可 (2021 年 11 月 19 日)
首个靶向癌症疗法获批以来,  20 年来已有 100 多种此类产品上市。这些靶向药物为地毯式化疗轰炸提供了一种不同的方法——它们是精确的导弹，瞄准肿瘤遗传学中的特定目标。上个月，美国食品和药物管理局 (FDA) 首次认可了将遗传生物标志物与特定癌症类型联系起来的精准肿瘤学知识库——斯隆凯特琳纪念癌症中心的肿瘤学知识库 (OncoKB)。 10 月，OncoKB 成为第一个被纳入 FDA 数据库列表的肿瘤突变数据库。 该列表包括 MSKCC 自己的 CBioPortal，以及本位癌症基因组MyCancerGenome、精准医学知识库the Precision Medicine Knowledge Base、癌症基因组解释器Cancer Genome Interpreter、癌症驱动程序日志Cancer Driver Log、肿瘤门户等Tumor Portal。